Your browser doesn't support javascript.
loading
Prolonged Exposure to ß-Lactam Antibiotics Reestablishes Susceptibility of Daptomycin-Nonsusceptible Staphylococcus aureus to Daptomycin.
Jenson, Rachel E; Baines, Sarah L; Howden, Benjamin P; Mishra, Nagendra N; Farah, Sabrina; Lew, Cassandra; Berti, Andrew D; Shukla, Sanjay K; Bayer, Arnold S; Rose, Warren E.
Afiliação
  • Jenson RE; School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Baines SL; Doherty Applied Microbial Genomics, Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Howden BP; Doherty Applied Microbial Genomics, Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Mishra NN; The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
  • Farah S; David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Lew C; The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
  • Berti AD; David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Shukla SK; School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Bayer AS; School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Rose WE; Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.
Article em En | MEDLINE | ID: mdl-32601160
Daptomycin-nonsusceptible (DAP-NS) Staphylococcus aureus often exhibits gain-in-function mutations in the mprF gene (involved in positive surface charge maintenance). Standard ß-lactams, although relatively inactive against methicillin-resistant S. aureus (MRSA), may prevent the emergence of mprF mutations and DAP-NS. We determined if ß-lactams might also impact DAP-NS isolates already possessing an mprF mutation to revert them to DAP-susceptible (DAP-S) phenotypes and, if so, whether this is associated with specific penicillin-binding protein (PBP) targeting. This study included 25 DAP-S/DAP-NS isogenic, clinically derived MRSA bloodstream isolates. MICs were performed for DAP, nafcillin (NAF; PBP-promiscuous), cloxacillin (LOX; PBP-1), ceftriaxone (CRO; PBP-2), and cefoxitin (FOX; PBP-4). Three DAP-NS isolates were selected for a 28-day serial passage in subinhibitory ß-lactams. DAP MICs and time-kill assays, host defense peptide (LL-37) susceptibilities, and whole-genome sequencing were performed to associate genetic changes with key phenotypic profiles. Pronounced decreases in baseline MICs were observed for NAF and LOX (but not for CRO or FOX) among DAP-NS versus DAP-S isolates ("seesaw" effect). Prolonged (28-d) ß-lactam passage of three DAP-NS isolates significantly reduced DAP MICs. LOX was most impactful (∼16-fold decrease in DAP MIC; 2 to 0.125 mg/liter). In these DAP-NS isolates with preexisting mprF polymorphisms, accumulation of additional mprF mutations occurred with prolonged LOX exposures. This was associated with enhanced LL-37 killing activity and reduced surface charge (both mprF-dependent phenotypes). ß-lactams that either promiscuously or specifically target PBP-1 have significant DAP "resensitizing" effects against DAP-NS S. aureus strains. This may relate to the acquisition of multiple mprF single nucleotide polymorphism (SNPs), which, in turn, affect cell envelope function and metabolism.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Daptomicina / Staphylococcus aureus Resistente à Meticilina Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Daptomicina / Staphylococcus aureus Resistente à Meticilina Idioma: En Ano de publicação: 2020 Tipo de documento: Article